Korsana

Employees
11–50
Business Model
B2B
Total Funding
$175.0M
Last Round
$150.0M Series AFeb 2026
Rounds
2

About

Korsana Biosciences is a Waltham, Massachusetts-based biopharmaceutical company developing precision-engineered therapies for neurodegenerative diseases, starting with Alzheimer's disease. In partnership with Paragon Therapeutics, Korsana has developed Therapeutic Targeting (THETA), a blood-brain-barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies. Its lead program, KRSA-028, is a next-generation shuttled monoclonal antibody targeting amyloid-beta plaques for Alzheimer's disease. The company emerged from stealth in February 2026 with $175 million in funding from investors including Venrock and Fairmount Funds Management.

Summary

Korsana is a Biotech company. It has raised $175.0M in total across 2 rounds, most recently a $150.0M Series A round in Feb 2026. Investors include Wellington Management, Fairmount and TCG Crossover.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AFeb 2026
$150.0M

Sign up to see all 2 events

Funding: Seed through Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Korsana on Indexed.vc
<a href="https://indexed.vc/companies/korsana"><img src="https://indexed.vc/api/badge/company/korsana" alt="Korsana on Indexed.vc" width="260" height="76" /></a>